Losartan to prevent hyperenzymemia after endoscopic retrograde cholangiopan-creatography: A randomized clinical trial

Table 1 Characteristics of the 76 participating patients and indications for their endoscopic retrograde cholangiopancreatography n (%)

Characteristic	Losartan group	Placebo group
Total	38 (100)	38 (100)
Study centre
Karolinska	19 (50)	19 (50)
Kalmar	19 (50)	19 (50)
Sex
Male	22 (58)	16 (42)
Female	16 (42)	22 (58)
Age, yr
< 65	13 (34)	14 (37)
≥ 65	25 (66)	24 (63)
Body mass index, kg/m2
< 20	3 (8)	2 (5)
20-25	14 (37)	14 (37)
> 25	7 (18)	9 (24)
Unknown	14 (37)	13 (34)
Previous pancreatitis
No	34 (89)	35 (92)
Yes	4 (11)	3 (8)
Indication for ERCP1
Jaundice without cholangitis	20 (53)	21 (55)
Jaundice with cholangitis	7 (18)	9 (24)
Suspected tumour in pancreas or bile ducts	10 (26)	13 (34)
Suspected benign disease, i.e., biliary lithiasis, stricture or other disease	20 (53)	16 (42)

¹Since each procedure could have several indications, the sum of percentages could be > 100. ECRP: Endoscopic retrograde cholangiopancreatography.